Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report

被引：13

作者：

Pinquie, Francois ^{[1
]}

de Chabot, Gonzagues ^{[1
]}

Urban, Thierry ^{[1
]}

Hureaux, Jose ^{[1
]}

机构：

[1] Univ Hosp Angers, Dept Pulmonol, Angers, France

来源：

ONCOLOGY | 2016年 / 90卷 / 03期

关键词：

Tyrosine kinase inhibitor; Non-small cell lung cancer; Heart failure; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; PHASE-3; EFFICACY; EVENTS; SAFETY;

D O I：

10.1159/000444186

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Erlotinib maintenance treatment improves progression-free survival compared with observation after first-line chemotherapy in unselected advanced non-small cell lung cancer (NSCLC). Very few cardiac adverse effects have been observed in phase III studies on tyrosine kinase inhibitors (TKI). We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. After 26 months of TKI therapy, she developed dilated cardiomyopathy. Despite symptomatic treatment, left ventricular ejection fraction decreased to 25%. Ischemic heart disease was excluded by coronary angiography and cardiac magnetic resonance imaging, and no other cause was found. Erlotinib was stopped, and cardiac resynchronization therapy by pacemaker was initiated. This case report highlights the possible cardiotoxic effects of long-term erlotinib and suggests the need for close clinical and echocardiographic follow-up of patients receiving long-term TKI therapy. (C) 2016 S. Karger AG, Basel

引用

页码：176 / 177

页数：2

共 10 条

[1] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[2] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[3] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes [J].

Doherty, Kimberly R. ;

Wappel, Robert L. ;

Talbert, Dominique R. ;

Trusk, Patricia B. ;

Moran, Diarmuid M. ;

Kramer, James W. ;

Brown, Arthur M. ;

Shell, Scott A. ;

Bacus, Sarah .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2013, 272 (01) :245-255

[4] Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition [J].

Force, Thomas ;

Krause, Daniela S. ;

Van Etten, Richard A. .

NATURE REVIEWS CANCER, 2007, 7 (05) :332-344

[5] Effects of tyrosine kinase inhibitors on rat isolated heart function and protein biomarkers indicative of toxicity [J].

Henderson, Kimberly A. ;

Borders, R. Brandon ;

Ross, John B. ;

Huwar, Theresa B. ;

Travis, Calvin O. ;

Wood, Brandon J. ;

Ma, Zhenxu J. ;

Hong, S. Peter ;

Vinci, Thomas M. ;

Roche, Brian M. .

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2013, 68 (01) :150-159

[6] Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure? [J].

Kus, Tulay ;

Aktas, Gokmen ;

Sevinc, Alper ;

Kalender, Mehmet Emin ;

Camci, Celaletdin .

ONCOTARGETS AND THERAPY, 2015, 8 :1341-1343

[7] Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors [J].

Lenihan, Daniel J. ;

Kowey, Peter R. .

ONCOLOGIST, 2013, 18 (08) :900-908

[8] Erlotinib in Advanced Non-small Cell Lung Cancer Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study [J].

Reck, Martin ;

van Zandwijk, Nico ;

Gridelli, Cesare ;

Baliko, Zoltan ;

Rischin, Danny ;

Allan, Simon ;

Krzakowski, Maciej ;

Heigener, David .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) :1616-1622

[9] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[10] Erlotinib in previously treated non-small-cell lung cancer [J].

Shepherd, FA ;

Pereira, JR ;

Ciuleanu, T ;

Tan, EH ;

Hirsh, V ;

Thongprasert, S ;

Campos, D ;

Maoleekoonpiroj, S ;

Smylie, M ;

Martins, R ;

van Kooten, M ;

Dediu, M ;

Findlay, B ;

Tu, DS ;

Johnston, D ;

Bezjak, A ;

Clark, G ;

Santabárbara, P ;

Seymour, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :123-132

← 1 →